Creative Touch Permanent Makeup and Aesthetics

Skin operates two independent barrier systems: the stratum corneum lipid bilayer, which governs transcellular water retention through its lamellar lipid organisation, and the tight junction barrier in the stratum granulosum, which governs paracellular permeability by sealing the spaces between living keratinocytes. Claudin-1 is the founding structural protein of the paracellular seal – its essential role was established definitively by the finding that claudin-1 knockout mice die within one day of birth from catastrophic TEWL despite morphologically intact keratinocyte layers. In human atopic dermatitis, claudin-1 expression is reduced in direct proportion to Th2 cytokine burden – IL-4, IL-13, and IL-33 all suppress CLDN1 through distinct signalling routes – and TEWL elevation follows a non-linear threshold relationship with claudin-1 reduction: barrier function is relatively stable until claudin-1 drops below approximately 45% of maximum expression, at which point TEWL rises sharply. Claudin-1 loss does not remain confined to the paracellular layer – it secondarily disrupts SC lipid lamellae architecture and suppresses filaggrin mRNA expression, making it an upstream driver of the SC deficits that are typically treated as the primary problem.

The Two-Barrier Model

The SC lipid bilayer accounts for the majority of barrier biology described in this knowledgebase – the ceramide triad, lamellar body secretion, filaggrin-NMF- acid mantle relationships, and elongase-dependent lipid synthesis. What that model describes is the transcellular barrier: water retained by the lipid organisation of the intercorneocyte space between dead corneocytes. The claudin-1 entity introduces the second, structurally independent barrier: the paracellular seal between living keratinocytes in the stratum granulosum, formed by tight junction protein complexes that physically close the lateral intercellular spaces.

These two barriers are not redundant – they govern different routes of trans-epidermal flux. The SC lipid bilayer primarily controls the transcellular route; the TJ barrier controls the paracellular route. Both are required for adequate barrier function; neither substitutes for the other. The founding evidence for this independence is unambiguous: claudin-1 knockout mice develop with morphologically normal keratinocyte architecture, normal SC structure, and intact corneocyte organisation – but die within 24 hours from dehydration because paracellular flux, without any TJ barrier to impede it, is incompatible with life. ^[5] An intact SC cannot compensate for absent TJ function.

Claudin-1 in the Stratum Granulosum

The stratum granulosum (SG) is the site of both lamellar body secretion – where SC lipid precursors are extruded into the intercorneocyte space – and tight junction assembly. Claudin-1 is the dominant claudin species in the SG TJ complex, where it partners with claudin-4 and occludin, with the complex anchored intracellularly to the actin cytoskeleton via ZO-1 and ZO-2 scaffold proteins. ^[2]

The TJ complex performs three distinct functions simultaneously: it provides the paracellular seal against water flux; it controls the paracellular movement of ions and small molecules that maintain the electrochemical gradient across the SG; and it maintains the compositional boundary between the extracellular environments above and below the SG – the below-SG environment being the relatively moist, ion-rich intercellular space of the viable epidermis, and the above-SG environment being the lipid-dominated SC interstitium. Claudin-1’s specific contribution is the primary sealing function; claudin-4 contributes ion selectivity; occludin contributes to barrier regulation and TJ complex integrity. Claudin-1 is indispensable; the others modulate but cannot substitute for it.

Claudin-1 is also expressed in the outer root sheath of the hair follicle, where it forms a TJ barrier at the follicular canal. ^[9] This follicular TJ expression is relevant to treatment penetration – the hair follicle is a known route for topical ingredient delivery, and the follicular claudin-1 barrier partially governs how much of what is applied at the follicular opening reaches the follicular canal depth.

The Threshold Effect and Non-Linear TEWL Response

The relationship between claudin-1 expression and barrier function in human atopic skin is not linear – and this non-linearity has direct clinical importance. Analysis of claudin-1 expression against TEWL in atopic skin (R² = 0.55, rₛ = −0.66) reveals a threshold at approximately 45% of maximum claudin-1 expression: above this threshold, TEWL remains relatively stable and barrier function is broadly maintained even with meaningful claudin-1 reduction; below it, TEWL rises sharply in a curve rather than a line. ^[3]

The clinical implication is that claudin-1 reduction in progressively sensitised or inflamed skin may be tolerated without measurable barrier consequence for a sustained period – during which the client has no subjective symptoms and no objective TEWL elevation – until the threshold is crossed, at which point barrier function deteriorates non-linearly and apparently suddenly. A client whose skin has been “fine” suddenly becoming reactive and sensitive, without any obvious external trigger change, may have crossed the CLDN1 threshold after a period of progressive cytokine-driven suppression.

Claudin-1 Loss Disrupts the SC Layer Downstream

Perhaps the most clinically consequential finding is that claudin-1 loss is not confined to the TJ layer – it has measurable consequences for the SC barrier above it. Claudin-1 knockdown in human epidermal models produces:

• Reduced intercellular lipid lamellae length in the SC – the structured lipid bilayers that the ceramide triad forms are shorter and less complete ^[3]
• Suppression of filaggrin mRNA expression – the TJ deficit impairs the signalling environment in which filaggrin transcription occurs ^[3]

This places claudin-1 upstream of filaggrin in one mechanistic pathway – a relationship that is typically assumed to run the other way in atopic dermatitis discussions. The standard framing is that filaggrin mutations compromise barrier function, which drives inflammation, which suppresses claudin-1. That pathway is real. But the reverse is also true: claudin-1 loss impairs filaggrin expression and SC lipid architecture, meaning that treatments targeting only the SC layer in presentations where TJ dysfunction is the primary driver will plateau because they are addressing a downstream consequence rather than the upstream failure.

Cytokine Suppression: The IL-4/IL-13/IL-33 Routes

Claudin-1 expression is suppressed by the same Th2 cytokine environment that drives the self-perpetuating barrier dysfunction loop described in the Barrier Dysfunction entity, through at least two distinct signalling routes:

IL-4 and IL-13 via JAK-STAT6: The primary Th2 cytokines activate STAT6, which downregulates CLDN1 transcription alongside filaggrin and loricrin. ^[4] This is the same JAK-STAT6 route through which IL-4/IL-13 suppresses elongase enzymes and filaggrin – CLDN1 suppression is not a separate inflammatory consequence but occurs in the same signalling event.

IL-33 via ERK/STAT3: IL-33 – the alarmin released by keratinocytes upon barrier disruption, upstream of the Th2 cascade – independently downregulates CLDN1 through ERK/STAT3 signalling. ^[8] This creates an additional suppression pathway that operates even before IL-4/IL-13 levels are substantially elevated, meaning CLDN1 reduction begins early in the cascade rather than only at its established phase.

The position of claudin-1 within the feedback loop: barrier disruption → keratinocyte TSLP/IL-33 release → early CLDN1 suppression via ERK/STAT3 → increased paracellular flux → more barrier disruption → Th2 IL-4/IL-13 → sustained CLDN1 suppression via JAK-STAT6 → SC lipid lamellae disruption + filaggrin mRNA suppression → SC barrier also impaired → further disruption. Claudin-1 is suppressed at two separate points in the loop rather than one.

Genetic Susceptibility: CLDN1 SNPs and Constitutive Deficit

Claudin-1 loss in atopic dermatitis is not entirely secondary to inflammation – some individuals carry constitutively lower claudin-1 expression as a genetic predisposition. Case-control studies have confirmed that CLDN1 haplotype SNPs associate with atopic dermatitis susceptibility, placing claudin-1 alongside filaggrin as a genetic barrier risk factor. ^[4] In these individuals the TJ barrier starts at a lower baseline, meaning the cytokine suppression that drives claudin-1 below the TEWL threshold requires less inflammatory stimulus – the threshold is easier to cross because the starting expression level is lower.

This genetic dimension has the same clinical relevance as FLG null mutations: clients with CLDN1 SNPs will have more reactive skin at lower levels of inflammatory challenge, will reach symptomatic threshold faster, and will require more sustained barrier support to remain above that threshold.

CLDN4 and the Divergent Atopic Pattern

Where claudin-1 is consistently downregulated in atopic dermatitis, claudin-4 shows a strikingly different pattern: it is frequently upregulated in AD skin, doing the opposite of claudin-1 in the same TJ complex. ^[6] The mechanism is not fully established – the upregulation may represent a compensatory response to claudin-1 loss attempting to partially restore TJ integrity, or it may represent a pathological cytokine-driven remodelling of the TJ complex composition.

Critically, CLDN4 upregulation does not compensate for CLDN1 loss. The two proteins have different barrier functions – claudin-1 provides the primary paracellular seal; claudin-4 primarily governs ion selectivity. Increasing CLDN4 in a CLDN1-deficient TJ complex does not restore paracellular water retention. The divergent regulation of CLDN1 and CLDN4 in atopic skin suggests that the cytokine environment remodels TJ complex composition rather than simply suppressing it – producing a structurally altered TJ that has even less barrier sealing capacity than a uniformly reduced complex would have.

The broader TJ scaffold – occludin and the ZO proteins – is also disrupted in atopic skin, confirming that the TJ deficit in AD is a complex remodelling event rather than a single protein loss. Claudin-1 is the primary functional target, but it does not exist in isolation.

The Systemic Dimension: Claudin-1 Across Epithelial Barriers

Claudin-1 is expressed not only in epidermal keratinocytes but in bronchial and intestinal epithelium, where it performs equivalent paracellular sealing functions. The same Th2 cytokine environment that suppresses CLDN1 in skin suppresses it simultaneously across all three epithelial surfaces – contributing to the atopic march pattern of AD progressing to asthma and food allergy through a unified mechanism of systemic barrier failure driven by shared cytokine suppression. ^[7] This is outside the scope of aesthetic clinical practice but is biologically important context for understanding why atopic clients often have a broader pattern of epithelial sensitivity beyond skin.